results of a randomized controlled trial by Biemann, Ronald et al.
1Scientific RepoRts | 6:30173 | DOI: 10.1038/srep30173
www.nature.com/scientificreports
Serum bile acids and GLP-1 
decrease following telemetric 
induced weight loss: results of a 
randomized controlled trial
Ronald Biemann1, Marina Penner1, Katrin Borucki1, Sabine Westphal1, Claus Luley1, 
Raik Rönicke1, Kathleen Biemann1, Cornelia Weikert2,3, Anke Lux4, Nikolai Goncharenko5, 
Hanns-Ulrich Marschall6, Jochen G. Schneider7,8,* & Berend Isermann1,*
Bile acids (BAs) are increasingly recognised as metabolic regulators, potentially improving insulin 
sensitivity following bariatric surgery. However, physiological relevance of such observations remains 
unknown. Hence, we analysed serum BA composition and associated gut-derived hormone levels 
following lifestyle-induced weight loss in individuals with metabolic syndrome (MetS). 74 non-smoking 
men (45–55 yr) with MetS were randomised to a lifestyle-induced weight loss program (supervision 
via telemonitoring) or to a control arm. Before and after a 6 months intervention period clinical and 
laboratory parameters, body composition, serum BA profile, FGF-19, and GLP-1 concentrations were 
determined in fasting blood samples. 30 participants in the control and 33 participants in the treatment 
arm completed the study and were included in the data analysis. In participants of the treatment arm 
lifestyle-induced weight loss resulted in markedly improved insulin sensitivity. Serum levels of BA 
species and total GLP-1 decreased, while FGF-19 remained stable. Serum BA composition changed 
towards an increased 12α-hydroxylated/non-12α-hydroxylated ratio. None of these parameters 
changed in participants of the control arm. Our results demonstrate that improved metabolic control 
by lifestyle modifications lowers serum levels of BAs and GLP-1 and changes serum BA composition 
towards an increased 12α/non-12α ratio (ICTRP Trial Number: U1111-1158-3672).
The clustering of diabetes, raised fasting plasma glucose, abdominal obesity, high cholesterol and high blood 
pressure, all well-established cardiovascular risk factors, is commonly referred to as the metabolic syndrome 
(MetS). Its increasing prevalence represents a major public health burden as individuals with MetS have twice the 
risk of developing cardiovascular disease (CVD) and a 5-fold elevated risk for type 2 diabetes1. Moreover, the risk 
for CVD and type 2 diabetes increases with the number of MetS components present2. So far, lifestyle-induced 
weight loss is regarded as efficient therapy to reverse MetS and to prevent type 2 diabetes and CVD in individuals 
with MetS3,4.
Bile acids (BAs) are considered to be important metabolic regulators5. In addition to their function in 
absorption of lipophilic nutrients, BAs act as ligands for the nuclear farnesoid X receptor (FXR) and the 
G-protein-coupled BA receptor (TGR5) that control intestinal secretion of fibroblast growth factor 19 (FGF-19) 
and the incretin glucagon-like peptide-1 (GLP-1)6–8. FGF19 and GLP-1 regulate glucose but also BA homeosta-
sis8–11. Hence, control of GLP-1 and FGF-19 secretion by BA receptors suggests a feedback loop between BAs and 
glucose homeostasis. Accordingly, it has been observed that bariatric surgery, e.g. gastric bypass surgery, which 
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may increase serum BA, FGF-19 and GLP-1 levels, is coupled with rapid resolution of insulin resistance and 
improved insulin secretion9,12–14. Furthermore, plasma BA composition was recently suggested as early biomarker 
for insulin resistance in healthy non-obese individuals15.
However, it remains unknown whether therapeutically altering of serum BA levels and/or composition may 
represent a useful target for interventions aiming to improve glucose metabolism in insulin resistant individu-
als9,10,16. Of note, prospective clinical studies evaluating the orchestrated changes of serum BA composition and 
associated gut-derived hormone levels (e.g. GLP-1, FGF-19) during conventional (lifestyle-induced) weight loss 
are lacking. To address the question how conventional weight loss affects BA metabolism in prediabetic indi-
viduals we prospectively determined the changes and interrelations of 15 endogenous BA species, clinical and 
metabolic parameters, and the intestinal hormones GLP-1 and FGF-19 following lifestyle-induced weight loss in 
74 well-defined individuals with MetS in a prospective study.
Results
Clinical and laboratory parameters. Thirty participants in the control and 33 participants in the telemon-
itored lifestyle-induced weight loss arm (Active Body Control, ABC, http://www.abcprogramm.de) completed the 
study (85% of the study population) and were included in the data analysis. 2 participants of the ABC arm and 4 
of the control arm did not follow the study protocol, and 3 participants of the control arm left the study because 
not being randomised to participate in the weight loss program. The remaining two dropouts of the ABC arm 
declined for undisclosed reasons. The study population did not differ in the distribution of age, sex and parame-
ters of the MetS (Table 1).
At baseline and after 6 months clinical parameters and body composition were determined in participants of 
both arms (Table 1). Participants of the ABC arm reduced their individual body weight by at least 5% (Fig. 1a). 
Notably, 76% reduced their body weight by at least 10% and 40% reduced their body weight by at least 15%. 
Absolute and relative weight reductions are given in supplementary Table S1. Reduction of body weight was 
mainly attributable to a significant reduction of individual body fat mass (− 23,57%, p < 0.001), especially in the 
trunk region (− 24.96%, p < 0.001). In controls, BMI and other parameters of the body composition remained 
unchanged and trunk fat mass even increased by 4.78%. In both groups, no progression to overt type 2 diabetes 
was observed.
ABC program led to significant reductions of systolic and diastolic blood pressure (− 7.69%, p < 0.001; and 
− 9.47%, p < 0.001), serum triglyceride levels (− 34.57%, p < 0.001), total cholesterol (− 8.70%, p < 0.001), LDL 
cholesterol (− 13.69%, p < 0.001), HbA1c (− 3.70%, relative value, p < 0.001), fasting blood glucose (− 6.10%, 
p < 0.001), fasting insulin (− 40.86%, p < 0.001) and HOMA-I (− 45.71%, p < 0.001), whereas HDL cholesterol 
increased (14.85%, p < 0.001). None of these parameters changed in participants of the control arm (Table 1). The 
observed changes of these clinical and laboratory parameters are in agreement with previous studies evaluating 
the efficacy of the ABC program in clinically distinct cohorts17,18.
BA profile. To assess the influence of lifestyle-induced weight loss on serum BAs, BA profiling was performed 
at baseline and after 6 months in both study arms. In order to avoid excessive multiple testing the 15 analysed BA 
species were grouped according to Table 2.
We observed a significant decrease of total BA levels in participants of the ABC arm (− 34.59%, p = 0.007) 
that resulted mainly from a decrease of glycine and taurine conjugated BAs (− 49.11%, p = 0.002 and − 54.46%, 
p = 0.001) (Fig. 1b and Supplementary Table S2). Regarding different BA-fractions, lifestyle-induced weight loss 
was accompanied by a significant decrease of total CDCA (− 52.38%, p = 0.001), CA (− 31.49%, p = 0.018) and 
UDCA (− 49.37%, p = 0.002) (Fig. 1c and Supplementary Table S2). The reduction of total CDCA and CA was 
caused by a decrease of the glycine or taurine conjugated BAs and the reduction of total UDCA was caused by a 
decrease of its unconjugated or glycine conjugated form (Supplementary Table S2). No significant alterations of 
the BA profile were observed in participants of the control arm. Taurine conjugated UDCA and taurine conju-
gated LCA were below the limit of detection in participants of both arms. As total LCA and DCA did not change, 
these BA groups were excluded from further analysis.
To determine whether the improvement of insulin sensitivity following lifestyle-induced weight loss was asso-
ciated with a reduction of the 12α -hydroxylated/ non-12α -hydroxylated ratio we next analysed these two BA 
subcategories in both arms. Contradictory to our hypothesis the decrease of non-12α -hydroxylated BAs was 
more pronounced than that of 12α -hydroxylated BAs, resulting in a significantly increased 12α -hydroxylated/ 
non-12α -hydroxylated ratio (p = 0.001) following lifestyle-induced weight loss (Fig. 1d, Supplementary Table S2). 
The detailed characterisation of the BA pool composition did not identify any BA species that increased during 
lifestyle-induced weight loss.
Fasting FGF-19 and total GLP-1 plasma levels. Lifestyle-induced weight loss had no effect on circu-
lating FGF-19 levels (Fig. 2a), while total GLP-1 decreased significantly (p = 0.003; Fig. 2b). Both parameters 
remained stable in the control arm. Hence, decrease of total GLP-1 may be attributed to lifestyle-induced weight 
loss and the associated metabolic improvements. Accordingly, relative changes of GLP-1 correlated significantly 
with relative changes of insulin, individual BAs and other metabolic parameters related to the MetS (Fig. 2c,d; 
Supplementary Table S3). Together, current results indicate an association between weight loss, serum BAs, insu-
lin and GLP-1.
Bivariate correlations between metabolic markers, BAs and GLP-1 during lifestyle-induced 
weight loss. We next determined bivariate correlations of relative changes of grouped BA fractions and 
GLP-1 between baseline and 6 month with relative changes of body weight and metabolic parameters that may 
influence BA metabolism, insulin, triglycerides and total cholesterol (Supplementary Table S3).
www.nature.com/scientificreports/
3Scientific RepoRts | 6:30173 | DOI: 10.1038/srep30173
We observed moderate to weak correlations between total BAs and GLP-1 (r = 0.54; p < 0.001), insu-
lin (r = 0.41; p < 0.001), triglycerides (r = 0.36; p = 0.004), cholesterol (r = 0.32; p = 0.011), and body weight 
(r = 0.28; p = 0.028).
Interestingly, changes of fasting insulin correlated with all analysed BA groups (Supplementary Table S3). 
Moderate correlations were observed between insulin and changes of total CDCA (r = 0.45; p < 0.001), total 
UDCA (r = 0.47; p < 0.001) and non-12α -hydroxylated BAs (r = 0.44; p < 0.001).
Total GLP-1 correlated moderately or weakly with relative changes of all analysed BA groups. Moderate to 
weak correlations were also found between GLP-1 and cholesterol (r = 0.42; p = 0.001), body weight (r = 0.39; 
p = 0.002), and insulin (r = 0.36; p = 0.005).
Taken together, our data support the existence of a feedback loop between BA, triglyceride and cholesterol 
metabolism that is associated with insulin and GLP-1.
Multiple regression analysis between BAs, GLP-1 and parameters of the metabolic syndrome. 
Because total BAs, individual BA subgroups and GLP-1 were correlated with relative body weight change, insulin, 
triglycerides and cholesterol, we performed a linear regression analysis to identify which of these variables are 
 
ABC Control





median 33,02 28.95* * * 33.41 33.57
IQR (31.16–35.75) (27.31–31.40) (31.7–37.07) (32.36–35.78)
body weight [kg]
median 111.0 95.0* * * 105.0 107.25
IQR (100.0–118.0) (85.45–103.15) (99.3–122) (99.5–122.25)
RRsys [mmHg]
median 142.0 130.0* * * 140.0 140.0
IQR (130.0–151.0) (120.0–135.0) (125–158.5) (130–140.5)
RRdia [mmHg]
median 90.0 82.0* * * 90.0 90.0
IQR (82.0–99.0) (80.0–86.0) (83.5–97.0) (80.0–93.0)
triglycerides [mmol/l]
median 2.06 1.37* * * 2.0 2.04
IQR (1.38–3.94) (1.09–1.99) (1.51–2.62) (1.54–3.55)
cholesterin [mmol/l]
median 6.16 5.69* * * 5.90 5.78
IQR (5.32–6.91) (4.50–6.31) (5.19–6.91) (4.99–7.07)
HDL-cholesterin [mmol/l]
median 1.20 1.41* * * 1.33 1.37
IQR (1.02–1.40) (1.19–1.58) (1.11–1.53) (1.11–1.51)
LDL-cholesterin [mmol/l]
median 3.74 3.35* * * 3.44 3.24
IQR (3.08–4.70) (2.37–4.11) (2.95–4.39) (2.65–4.14)
fasting insulin [pmol/l]
median 88.0 47.0* * * 62.5 61.0
IQR (59.0–134.0) (25.0–70.0) (50.0–88.5) (47.0–90.25)
fasting glucose [mmol/l]
median 6, 12 5.53* * * 5.95 5.93
IQR (5.61–6.31) (5.25–5.97) (5.55–6.27) (5.43–6.36)
HOMA
median 3.15 1.71* * * 2.40 2.20
IQR (2.19–5.01) (0.94–2.56) (1.89–3.31) (1.66–3.78)
HbA1c [%]
median 5.60 5.40 * * * 5.60 5.60
IQR (5.30–6.05) (5.20–5.60) (5.37–5.85) (5.30–5.80)
HbA1c [mmol/mol]
median 37.0 35.0* * * 38.0 37.0
IQR (34.0–43.0) (33.0–37.0) (35.5–40.5) (34.75–40.0)
fat mass [kg]
median 31.69 22.98* * * 28.23 30.02
IQR (25.86–36.31) (20.30–28.46) (25.43–40.6) (25.44–40.77)
trunk fat mass [kg]
median 17.91 13.38* * * 17.43 18.14
IQR (15.24–21.80) (10.39–16.32) (14.15–23.48) (14.27–23.15)
fat free mass [kg]
median 75.55 70.36* * * 72.91 73.46
IQR (67.69–78.69) (65.25–74.88) (68.65–79.28) (69.39–79.87)
ALAT [μ mol/s·l]
median 0.64 0.40* * * 0.74 0.685
IQR (0.515–0.975) (0.320–0.535) (0.46–1.07) (0532–1.052)
ASAT [μ mol/s·l]
median 0.48 0.41* * * 0.500 0.530
IQR (0.43–0.65) (0.34–0.44) (0.395–0.615) (0.407–0.632)
Table 1.  Clinical characteristics of subjects with MetS who underwent lifestyle-induced weight loss (ABC) 
and controls at baseline and after 6 months. Data are presented as median (interquartile range). Wilcoxon 
Signed-Rank Test was used to analyse differences of paired samples with N = 33 ABC, N = 30 control, * * * p < 0.01. 
No differences were found between ABC vs. control at baseline, analysed by Mann-Whitney U Test.
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predictive for changes of BAs and GLP-1 by backward elimination. Considering relative changes of body weight, 
insulin, triglycerides and cholesterol as independent determinant variables, we observed associations between 
body weight and total CDCA (β = 0.28; p = 0.030) and non-12α -hydroxylated BAs (β = 0.28; p = 0.028), between 
insulin and total UDCA (β = 0.36; p = 0.004) and total taurine conjugated BAs (β = 0.34; p = 0.008), between 
triglycerides and total secondary BAs (β = 0.25; p = 0.030) and between cholesterol and total GLP-1 (β = 0.34; 
p = 0.009).
None of these BA groups were determined by more than one of the selected variables and the determinant 
variables differed for each group. We have not identified associations between BA groups and changes of choles-
terol, indicating that cholesterol levels do not predict serum BA pool composition. In summary, our data indicate 
that relative changes of body weight, insulin, triglycerides and cholesterol are not predictive for BA changes in a 
common model.
Discussion
We analysed the relationship between individual endogenous BA levels and metabolic parameters following 
lifestyle-induced weight loss in individuals with MetS. Remarkably, weight loss was accompanied by a signifi-
cant reduction of serum BA concentrations and GLP-1 levels. Lifestyle-induced changes of BAs and GLP-1 were 
correlated with changed levels of insulin, cholesterol, and triglycerides. FGF-19 levels did not change follow-
ing lifestyle-induced weight loss, indicating that intestinal FGF-19 and GLP-1 secretion might not be coupled. 
Detailed analysis of BA species showed that no individual BA increased. Multiple regression analysis revealed that 
clinical and metabolic parameters, i.e. body weight, plasma insulin, triglycerides and cholesterol, are not suitable 
to predict serum BA composition by a common model.
Our data are in contrast to observations made in patients who underwent gastric bypass surgery, which is 
characterised by an increase of BAs, FGF-19 and GLP-1 concentrations9,12–14. BA increase following gastric bypass 
surgery has been shown to be biphasic, with an early increase (one month post-surgery) of UDCA and its con-
jugates and a gradual increase within 24 months post-surgery of CDCA, CA, DCA and GDCA19. Hence, it is 
discussed that the increase of BA species may promote early improvement of insulin sensitivity following gastric 
bypass surgery independently from weight loss. However, other bariatric surgery procedures that preserve integ-
rity of the intestine, like laparoscopic sleeve gastrectomy or gastric banding, are not associated with elevated BA 
levels, despite improved insulin sensitivity16,20–22. Taken together, surgical manipulations of the intestine increase 
or at least prevent a weight loss associated decrease of BAs, as observed in the current study. It is possible that 
Figure 1. Changes of body weight and bile acid (BA) fractions in subjects with MetS who underwent lifestyle-
induced weight loss (ABC) and in controls. Body weight was daily telemonitored in participants who attended the 
lifestyle-induced weight loss program and median weight progress is demonstrated as bold line (a). Concentrations 
of conjugated BAs (b) and BA fractions (c) at baseline and 6 months are shown as bar graphs. Ratio between 12α 
-hydroxylated BAs and non-12α -hydroxylated BAs (c). Wilcoxon Signed-Rank Test was used to analyse differences 
between paired samples; data are presented as median ± interquartile range; * p < 0.05; * * p < 0.01; * * * p < 0.01.
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bariatric surgery procedures are accompanied by an altered enterohepatic recirculation of BAs9,13, which counter-
acts a weight loss associated decrease of serum BA levels.
Despite different post-surgery BA-responses the weight-adjusted long-term improvement of insulin sensitivity 
is comparable following laparoscopic sleeve gastrectomy, gastric banding, or bariatric bypass surgery23. Indeed, 
some authors argue that reduced caloric intake and weight loss, but not increased serum BA levels, improve glu-
cose metabolism following bariatric surgery10,16. The current results, demonstrating that serum BA levels even 
decrease following lifestyle-induced weight loss, support the argument that reduced caloric intake and weight 
loss, and not increased serum BA levels, improve insulin sensitivity.
Since lifestyle-induced weight loss is accompanied by reduced serum BA concentrations, it might be possible 
that attenuated activation of FXR promotes the development of hepatic steatosis24. Hepatic steatosis is strongly 
associated with insulin resistance and various features of the MetS. Insulin stimulates SREBP1c mRNA transcrip-
tion and posttranslational proteolytic activation, leading to an activation of hepatic lipogenic gene expression25. 
However, our results demonstrate that lifestyle-induced weight loss, which leads to improved insulin sensitivity, 
is associated with reduced serum TG, ALAT and ASAT levels. Thus, our results indicate that reduced serum BA 
levels following lifestyle-induced weight loss in individuals with MetS are not associated with hepatic steatosis.
Our data raise the question as to why BA levels that were reported to be increased in individuals with 
MetS15,26,27 decrease following weight-loss associated improvement of insulin sensitivity. 95% of the BAs are reab-
sorbed at the distal ileum and transported back to the liver via portal circulation, where > 90% of reabsorbed BAs 
are efficiently extracted. It has been shown that primary BA pool size represents a major determinant of serum 
BA levels following cholecystokinin treatment28. Based on this, it is suggested that serum BA concentrations 
reflect spillover of BAs into systemic circulation. In healthy individuals, hepatic BA synthesis is inhibited by BAs 
itself via activation of FXR, with CDCA being the most efficacious endogenous FXR ligand29. Activation of FXR 
inhibits transcription of the critical regulatory gene in BA synthesis, cholesterol 7alpha-hydroxylase (CYP7A1). 
Several observations indicate that this feedback mechanism is impaired in diabetes30–32. Accordingly, it was 
shown that FXR gene expression is controlled by insulin and reduced under diabetic conditions31. Our results 
demonstrate that the decrease of serum BA levels correlated with reduced fasting insulin levels. Hence, we assume 
that improved insulin sensitivity following lifestyle-induced weight loss restored physiologic control of FXR by 
BAs, resulting in reduced serum BA levels. Our data suggest that reduced BA levels are a consequence and not a 
cause of improved metabolic control during lifestyle-induced weight loss.
Different BA species have distinct selectivity for BA receptors. Thus, alterations of serum BA composition 
may interfere with metabolic functions. To our knowledge, this is the first study describing alterations of BA 
composition following life style induced weight loss in human individuals. The decrease of BAs was mainly 
restricted to CDCA (non-12α -hydroxylated primary BA), its secondary metabolite UDCA, and to a lesser extent 
to CA (12α -hydroxylated primary BA). Weight loss resulted in an increased ratio of 12α -hydroxylated/ non-
12α -hydroxylated BAs. The ratio of CA (12α -hydroxylated) over CDCA (non-12α -hydroxylated) is controlled by 
hepatic CYP8B1, which is responsible for the synthesis of CA and its derivatives33. The 12α -hydroxylated BAs CA 
and DCA are reported to be elevated in insulin resistant individuals5,15,34 and genetic deletion of CYP8B1 in mice 
Name (abbrevation) Conjugated Primary 12α-OH
uncon. CDCA x
 




∑ CAglycine_CA x x x
taurine_CA x x x
uncon. DCA
 










Table 2.  Subgrouping of the measured bile acids. CDCA, chenodeoxycholic acid; CA, cholic acid; DCA, 
deoxycholic acid; UDCA, ursodeoxycholic acid; LCA, lithocholic acid; 12α -OH, 12α -hydroxylated BAs.
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leads to improved glucose tolerance35. Based on those observations our results may appear unexpected. However, 
an increased ratio of 12α -hydroxylated/ non-12α -hydroxylated BAs was also observed 2 years after bariatric sur-
gery36, suggesting a common mechanism that might be mediated by improved hepatic insulin sensitivity.
Another potential factor, which may contribute to the decreased serum BA concentrations, is an altered first 
pass extraction by the liver. Furthermore, BA pool composition depends on the gut microbiome, which might be 
changed following lifestyle-induced weight loss. Bacteria convey intestinal deconjugation and dihydroxylation of 
primary BAs, which gives rise to the secondary BAs DCA, LCA and UDCA30,37. The possible relevance of the gut 
microbiome for the observed alterations of serum BA composition was not addressed in the current study and 
awaits further investigations.
Enhanced faecal elimination of BAs by a fibre rich diet, as recommended to the study participants, is another 
potential cause for the decreased serum BA concentrations. The dietary intake was not monitored in the current 
study and therefore BA reduction cannot be correlated to the actually fibre intake. However, faecal BA loss is 
typically compensated by an enhanced hepatic LDL uptake and by an enhanced synthesis of BAs. FGF-19 acts as a 
negative feedback regulator of hepatic BA synthesis38, and increased intestinal BA elimination by sequestrants or a 
fibre rich diet results in decreased intestinal FGF-19 secretion and lower FGF-19 plasma levels39. Yet we observed 
no change of FGF-19 levels following weight loss, arguing against faecal BA elimination as a major factor contrib-
uting to the observed BA reduction.
Glucose homeostasis is thought to be improved by BAs through induction of intestinal GLP-1 secretion via 
activation of TGR56. In concordance with that, gastric bypass surgery is associated with increased plasma levels 
of GLP-112, even in the fasting state14. GLP-1 is an incretin and a potent stimulator of insulin secretion from 
pancreatic β -cells, thus promoting postprandial glucose clearance. Furthermore, GLP-1 inhibits gastric emptying 
and promotes satiety40,41.
Unlike gastric bypass surgery lifestyle-induced weight loss was not associated with elevated GLP-1 levels in 
our study. Instead, we observed decreased levels of fasting GLP-1. The decreased levels of fasting GLP-1 were 
correlated with changes of insulin and total BA levels. Furthermore, multiple regression analysis revealed an 
association between cholesterol and GLP-1. It has been shown that elevated fasting levels of GLP-1 are associated 
with MetS components42 and that decreased fasting GLP-1 levels correlate with fasting insulin levels in obese 
Figure 2. Changes of fibroblast growth factor 19 (FGF-19) and glucagon-like peptide-1 (GLP-1) in subjects 
with MetS who underwent lifestyle-induced weight loss (ABC) and in controls. Concentrations of FGF-19 
(a) and GLP-1 (b) are shown as individual data points and median ± interquartile range. Wilcoxon Signed-Rank 
Test was used to analyse differences between paired samples; * * p < 0.01. Spearman correlation (2-tailed) was 
used to analyse correlation between relative changes of insulin (c) and GLP-1 or total bile acids (BA) and GLP-1 
(d) respectively. Data are shown as individual data points. Regression line is given as mean ± 95% confidence 
interval.
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individuals who reduced body weight by dietary changes43. Based on these studies, we assume that the observed 
reduction of GLP-1 may reflect recovered metabolic homeostasis following lifestyle-induced weight loss.
Strengths of the current study include the prospective study design, a well characterised study population 
with no differences between groups at baseline, a low dropout rate and high compliance of participants as a result 
of daily telemonitoring and weekly letters commenting individual weight progress. Laboratory technicians were 
blinded regarding to the status of the samples and all laboratory measurements were performed according to 
standard operating protocols. As a result, obtained data are of high quality. On the other hand, the current study 
is limited to middle aged male caucasian participants with MetS. Thus the results cannot be generalised to other 
racial/ethnic groups and to individuals without MetS. Weight loss in the present study was less pronounced 
compared to bariatric surgery and the observational period was limited to 6 months. Hence, our study does not 
address longitudinal changes in serum BA levels following endogenous weight loss. Another limitation is that 
only fasting levels were measured. Therefore, we cannot comment on postprandial changes of serum BAs. The 
impact of an endogenous weight loss on postprandial serum BA levels remains to be evaluated in future studies. 
Furthermore, total GLP-1 was estimated instead of active GLP-1. Active GLP-1 has a very short half-life and 
is found in low concentrations, before it is degraded by DPP-IV, while total GLP-1 gives an indication of the 
secretion from intestinal L-cells. However, total GLP-1 has been shown to positively correlate with active GLP-1 
concentration44.
Taken together, using a telemonitored program we achieved a pronounced weight loss and metabolic improve-
ment in obese, pre-diabetic individuals. Importantly, in contrast to bariatric surgery lifestyle-induced weight 
loss results in a decrease of serum BA and GLP-1 concentrations without affecting FGF-19. These changes are 
associated with specific alterations of serum BA composition resulting in an increased 12α -hydroxylated/non-
12α -hydroxylated ratio. Therefore, lifestyle-induced metabolic changes cannot be explained by increased serum 
levels of BAs, GLP-1, or FGF-19. Current results suggest instead that lower levels of BAs and GLP-1 are the 
consequence of improved insulin sensitivity and the associated recovered metabolic homeostasis. These results 
provide important novel insights regarding the role of BAs in glucose homeostasis and their therapeutic potential 
for insulin resistance.
Materials and Methods
Research design. The study is embedded in a prospective, two-armed, controlled, mono-centric, ran-
domised, 6-months intervention trial to identify changes of the mRNA and microRNA expression profile of 
individuals with metabolic syndrome following lifestyle-induced weight loss. For this purpose paired blood 
samples and subcutaneous adipose tissue biopsies were collected at the Institute of Clinical Chemistry and 
Pathobiochemistry, Otto-von-Guericke University, Magdeburg, Germany. The trial was registered at the German 
Clinical Trials Register (ICTRP Trial Number: U1111-1158-3672) in July 2014.
The trial included non-smoking, non-diabetic men aged between 45 and 55 years with MetS as defined by the 
National Cholesterol Education Program Adult Treatmen Panel III guideliens: abdominal obesity (waist circum-
ference > 102 cm or BMI > 30 kg/m2) combined with at least two of the following criteria: fasting triglyceride con-
centration ≥ 1.7 mmol/l; high-density lipoprotein (HDL) cholesterol < 1.05 mmol/l; fasting glucose ≥ 5.6 mmol/l; 
blood pressure ≥ 130/85 mmHg or treatment for hypertension. Exclusion criteria were smoking, diabetes melli-
tus type 2, surgical procedure for weight loss within the previous 6 months, severe renal dysfunction (creatinin 
concentration > 2.0 mg/dl), active liver disease, obesity of known endocrine origin or inability to walk at least 
30 minutes per day. Participants were recruited by an advertisement in a regional newspaper. Out of 133 individ-
uals screened for inclusion or exclusion criteria from May 2012 to August 2012, 74 individuals were selected for 
the trial. All participants underwent a structured education about diet and the importance of physical activity. 
Individuals were randomly assigned to a 6 months lasting telemonitored lifestyle-induced weight loss program 
(ABC) or a control arm by a web-based randomisation tool using permuted block randomisation with stratifica-
tion on BMI (Randomisation In Treatment Arms (RITA); University of Lübeck, Germany). A blinded investigator 
who did not have any interaction with the participants during the screening and enrolment process managed 
group allocation assignments. Participants of both arms were linked to an identification number and samples 
were collected in sequentially numbered containers. Hence, laboratory technicians were blinded regarding to 
the status of the samples. Participants of the ABC arm received accelerometers measuring their daily activity 
and instructions for daily data transmission of body weight, physical activity and approximated caloric intake17. 
Participants of the ABC arm received regular feedback by weekly letters commenting their individual weight pro-
gress and daily exercise-related energy expenditure. At baseline and after 6 months subcutaneous adipose tissue 
biopsies and peripheral blood samples were obtained from participants of both arms. All study participants were 
examined after 3 months and screened for fasting blood glucose and glycated haemoglobin (HbA1c) to prevent 
complications secondary to progression to overt type 2 diabetes. Expression profile of microRNAs in paired blood 
and subcutaneous adipose tissue will be analysed as primary outcome (not part of this report). Changes of bile 
acid concentrations were quantified as secondary outcome at baseline and at the end of the study period in paired 
serum samples.
Ethics Statement. This study was approved by the ethics committee at Otto-von-Guericke University, 
Magdeburg, Germany (No. 78/11). Written informed consent was obtained from all study participants. All 
human investigations were conducted according to the principles expressed in the Declaration of Helsinki.
Clinical and laboratory parameters. Body weight, height, waist circumference and blood pressure 
were measured by qualified medical personnel according to standard operating protocols at baseline and after 6 
months. Body composition was analysed by dual-energy X-ray absorptiometry.
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All blood samples were collected in the morning (8 am to 9 am) from the antecubital vein after a 12-hour 
overnight fast. BA profiling was performed by high performance liquid chromatography-tandem mass spectrom-
etry at the Department of Clinical Chemistry, Karolinska University Hospital Huddinge, Stockholm, Sweden. 
Deuterium labelled unconjugated and glycine or taurine conjugated BAs were used as internal standards for 
quantification of the primary and secondary BAs CA, CDCA, DCA, LCA and UDCA45.
All other laboratory measurements were performed at the Institute of Clinical Chemistry and 
Pathobiochemistry, OvGU, Magdeburg, Germany. Fasting blood glucose, triglycerides, ALAT, ASAT, low-density 
lipoprotein (LDL) cholesterol, HDL cholesterol and total cholesterol were analysed by commercial enzymatic 
methods using a random-access analyser (Modular, Roche Diagnostics, Mannheim, Germany). Lipoprotein 
fractions were analysed by ultracentrifugation. Glucose was determined in sodium fluoride plasma. HbA1c was 
determined by high performance liquid chromatography. Insulin was determined by 125I-radioimmunoassay 
(RIA) according to the manufacturer’s instructions (INSULIN-CT, CIS bio, Berlin, Germany).
The homeostasis model of assessment index (HOMA-I) was calculated using fasting insulin and glucose val-
ues46. Plasma FGF-19 concentrations were determined by a commercial ELISA assay (FGF-19 Quantikine ELISA, 
R&D Systems, Minneapolis, Minnesota, USA). Total plasma GLP-1 was analysed using a RIA with antibodies 
targeting the C-terminal of GLP-1 after ethanol extraction (GLP1T-36HK, Linco Research, St. Charles, Missouri, 
USA), according to manufacturer’s instructions.
Statistical analysis. Sample size was determined to characterize the expression profile of microR-
NAs in paired blood and subcutaneous adipose tissue from individuals with MetS following lifestyle-induced 
weight loss. The following sample size computational model was used: http://bioinformatics.mdanderson.org/
MicroarraySampleSize/MicroarraySampleSize.aspx. We aimed to target the upper 75th percentile as level of var-
iance across all genes and applied a level of 0.65 as a realistic value for standard deviation of the gene intensity 
measurement on the base-2 logarithmic scale for genes that are expressed at moderate to high levels47. This calcu-
lation resulted in a sample size of n = 29 required for detecting a 1.5-fold change in 75% least variable genes with 
a two sided 0.001 significance level (false positive rate of 1%) and power of 80%. With a supposed dropout rate of 
20% 37 individuals had to be recruited for each group.
Changes of bile acid concentrations were quantified as secondary outcome. As data of BA-profiling were not 
normally distributed, non-parametric tests were applied for all statistical analysis. Data are given as median and 
interquartile range (IQR). Differences between independent samples (ABC vs. control at baseline or 6 month, 
respectively) were analysed by Mann-Whitney U Test. Paired samples were analysed by Wilcoxon Signed-Rank 
Test. Correlations between relative changes of BAs and other variables were assessed by Spearman’s rank correla-
tion. Multiple linear regression analysis with backward elimination was used to identify which of the determinant 
variables that were significantly changed after weight loss and may influence BA metabolism (body weight, insu-
lin, cholesterol, triglycerides) were independently associated with altered BA groups or GLP-1. All calculations 
were performed using the IBM® SPSS® Statistics, version 22.0 (IBM Corporation, Armonk, NY, USA). Results 
were considered significant at P < 0.05.
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